









市場行情
/
股票
/
nasdaq-argx
/

argenx SE

ARGX

877.940USD

-11.550-1.30%

收盤 12/12, 16:00（美東）報價延遲15分鐘

53.70B總市值

34.64本益比TTM



argenx SE

877.940

-11.550-1.30%

概覽公司財務分析

概覽

公司

財務

分析

關於 argenx SE 公司

argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.

argenx SE簡介



公司代碼ARGX

公司名稱argenx SE

上市日期Jul 10, 2014

CEOvan Hauwermeiren (Tim)

員工數量1599

證券類型Depository Receipt

年結日Jul 10

公司地址Laarderhoogtweg 25

城市AMSTERDAM

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Netherlands

郵編1101 EB

電話31763030

網址https://www.argenx.com/

公司代碼ARGX

上市日期Jul 10, 2014

CEOvan Hauwermeiren (Tim)

argenx SE公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Karl Gubitz

Chief Financial Officer

500.00

Mrs. Camilla Sylvest

Non-Executive Independent Director

Mr. Tim van Hauwermeiren

Chief Executive Officer, Co-Founder, Executive Director

Dr. Ana Cespedes

Non-Executive Independent Director

Ms. Karen Massey

Chief Operating Officer

Mrs. Andria Wilk

Global Head of Quality

Mr. Arjen Lemmen

Vice President - Corporate Development and Strategy

Ms. Malini Moorthy

General Counsel

Mr. Peter Ulrichts

Chief Scientific Officer

Mr. Peter K. M. Verhaeghe

Non-Executive Independent Chairman of the Board

名稱

名稱/職務

職務

持股

持股變動

Mr. Karl Gubitz

Chief Financial Officer

500.00

Mrs. Camilla Sylvest

Non-Executive Independent Director

Mr. Tim van Hauwermeiren

Chief Executive Officer, Co-Founder, Executive Director

Dr. Ana Cespedes

Non-Executive Independent Director

Ms. Karen Massey

Chief Operating Officer

Mrs. Andria Wilk

Global Head of Quality

收入明細

單位: USD更新時間: 10月6日週一

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

由於公司未披露，未能獲取相關數據

地區USD

名稱

營收

佔比

United States

1.90B

86.56%

Rest of the World

161.25M

7.36%

Japan

89.39M

4.08%

China

43.52M

1.99%

Netherlands

153.00K

0.01%

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月18日週二

持股股東

股東類型

持股股東

佔比

Fidelity Management & Research Company LLC

8.96%

T. Rowe Price Associates, Inc.

4.60%

Janus Henderson Investors

4.21%

Artisan Partners Limited Partnership

3.57%

Capital World Investors

3.20%

其他

75.46%

持股股東

佔比

Fidelity Management & Research Company LLC

8.96%

T. Rowe Price Associates, Inc.

4.60%

Janus Henderson Investors

4.21%

Artisan Partners Limited Partnership

3.57%

Capital World Investors

3.20%

其他

75.46%

股東類型

持股股東

佔比

Investment Advisor

27.69%

Investment Advisor/Hedge Fund

16.94%

Hedge Fund

4.43%

Research Firm

1.11%

Pension Fund

0.38%

Private Equity

0.31%

Bank and Trust

0.10%

Family Office

0.01%

其他

49.03%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

855

32.28M

58.19%

+72.85K

2025Q3

891

32.22M

58.55%

-544.28K

2025Q2

847

32.65M

61.10%

-1.53M

2025Q1

821

34.16M

62.26%

-3.81M

2024Q4

770

34.96M

63.31%

-1.04M

2024Q3

718

36.05M

63.46%

+556.56K

2024Q2

690

35.13M

62.09%

+253.45K

2024Q1

672

34.89M

59.82%

-632.92K

2023Q4

654

33.46M

57.06%

+708.68K

2023Q3

609

32.76M

55.78%

+1.52M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Fidelity Management & Research Company LLC

5.21M

8.52%

-251.10K

-4.59%

Jun 30, 2025

T. Rowe Price Associates, Inc.

4.09M

6.69%

-498.08K

-10.85%

Jun 30, 2025

Janus Henderson Investors

2.57M

4.19%

+422.32K

+19.71%

Jun 30, 2025

Artisan Partners Limited Partnership

2.35M

3.84%

-436.11K

-15.65%

Jun 30, 2025

Capital World Investors

1.95M

3.19%

+13.09K

+0.68%

Jun 30, 2025

Avoro Capital Advisors LLC

1.18M

1.92%

-60.18K

-4.87%

Jun 30, 2025

T. Rowe Price International Ltd

887.87K

1.45%

+93.47K

+11.77%

Jun 30, 2025

ClearBridge Investments, LLC

772.87K

1.26%

+108.50K

+16.33%

Jun 30, 2025

Wellington Management Company, LLP

405.33K

0.66%

-871.00

-0.21%

Jun 30, 2025

Citadel Advisors LLC

865.97K

1.42%

+314.03K

+56.90%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

VanEck Biotech ETF

5.04%

iShares Neuroscience and Healthcare ETF

4.22%

Goldman Sachs Future Health Care Equity ETF

3.92%

First Trust NYSE Arca Biotechnology Index Fund

3.45%

iShares Biotechnology ETF

3.12%

PGIM Jennison International Opportunities ETF

2.55%

ProShares Ultra Nasdaq Biotechnology

2.46%

Invesco Nasdaq Biotechnology ETF

2.44%

American Century Mid Cap Growth Impact ETF

1.63%

Invesco NASDAQ Next Gen 100 ETF

1.37%

VanEck Biotech ETF

佔比5.04%

iShares Neuroscience and Healthcare ETF

佔比4.22%

Goldman Sachs Future Health Care Equity ETF

佔比3.92%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.45%

iShares Biotechnology ETF

佔比3.12%

PGIM Jennison International Opportunities ETF

佔比2.55%

ProShares Ultra Nasdaq Biotechnology

佔比2.46%

Invesco Nasdaq Biotechnology ETF

佔比2.44%

American Century Mid Cap Growth Impact ETF

佔比1.63%

Invesco NASDAQ Next Gen 100 ETF

佔比1.37%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

argenx SE的前五大股東是誰？



argenx SE的前五大股東如下：
Fidelity Management & Research Company LLC
持有股份：5.21M
佔總股份比例：8.52%。
T. Rowe Price Associates, Inc.
持有股份：4.09M
佔總股份比例：6.69%。
Janus Henderson Investors
持有股份：2.57M
佔總股份比例：4.19%。
Artisan Partners Limited Partnership
持有股份：2.35M
佔總股份比例：3.84%。
Capital World Investors
持有股份：1.95M
佔總股份比例：3.19%。